The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy

BACKGROUND: Atezolizumab, an immune checkpoint inhibitor, in combination with chemotherapy (chemoimmunotherapy) has become a first-line treatment option for metastatic non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) are self-reported measures that have shown promise in their pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Badaoui, Sarah, Shahnam, Adel, McKinnon, Ross A., Abuhelwa, Ahmad Y., Sorich, Michael J., Hopkins, Ashley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988084/
https://www.ncbi.nlm.nih.gov/pubmed/35399575
http://dx.doi.org/10.21037/tlcr-21-938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988084/
https://www.ncbi.nlm.nih.gov/pubmed/35399575
http://dx.doi.org/10.21037/tlcr-21-938

Ejemplares similares